ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.971,77
-0,30%
S&P 500
6.086,37
0,61%
US Dollar vs BRL
5,9437
0,03%
Bitcoin
103.276,98
-0,35%
Brent Oil
78,335
0,00%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Calliditas Therapeutics AB (CALT)

  7. Calliditas Therapeutics AB (CALT) Notícias

CALT

Calliditas Therapeutics AB (CALT)

Calliditas Therapeutics AB
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CALT
DataHoraFonteTítuloCódigoCompanhia
23/09/202417:44Edgar (US Regulatory)Form 15F-12B - Securities registration termination of foreign private issuers [Section 12(b)]NASDAQ:CALTCalliditas Therapeutics AB
16/09/202410:46PR Newswire (US)Delisting of Calliditas Therapeutics AB (publ) from Nasdaq StockholmNASDAQ:CALTCalliditas Therapeutics AB
03/09/202408:13PR Newswire (US)Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
03/09/202407:33PR Newswire (US)Calliditas Therapeutics takes certain corporate actions following announcement by Asahi KaseiNASDAQ:CALTCalliditas Therapeutics AB
13/08/202402:25PR Newswire (US)Calliditas Interim Report January to June 2024NASDAQ:CALTCalliditas Therapeutics AB
05/08/202402:26PR Newswire (US)Invitation to the presentation of Calliditas´s interim report January - June 2024NASDAQ:CALTCalliditas Therapeutics AB
01/08/202410:00GlobeNewswire Inc.Calliditas Therapeutics to Attend 2024 Women in Nephrology (WIN) Leadership ConferenceNASDAQ:CALTCalliditas Therapeutics AB
31/07/202409:23PR Newswire (US)Number of shares and votes in Calliditas TherapeuticsNASDAQ:CALTCalliditas Therapeutics AB
26/07/202417:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CALTCalliditas Therapeutics AB
26/07/202412:23PR Newswire (US)Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA NephropathyNASDAQ:CALTCalliditas Therapeutics AB
26/07/202403:29PR Newswire (US)Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitisNASDAQ:CALTCalliditas Therapeutics AB
04/07/202404:44PR Newswire (US)Launch of Phase 3 clinical trial with Nefecon in JapanNASDAQ:CALTCalliditas Therapeutics AB
18/06/202407:25PR Newswire (US)Calliditas provides setanaxib patent updateNASDAQ:CALTCalliditas Therapeutics AB
17/06/202413:01PR Newswire (US)Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
30/05/202415:20PR Newswire (US)Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathyNASDAQ:CALTCalliditas Therapeutics AB
28/05/202409:46PR Newswire (US)Calliditas Therapeutics Presents Data at the 61st European Renal Association CongressNASDAQ:CALTCalliditas Therapeutics AB
28/05/202409:09Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:CALTCalliditas Therapeutics AB
28/05/202404:17PR Newswire (US)Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei CorporationNASDAQ:CALTCalliditas Therapeutics AB
23/05/202402:55PR Newswire (US)Calliditas Q1 report, January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
16/05/202403:45PR Newswire (US)Invitation to the presentation of Calliditas´s interim report January - March 2024NASDAQ:CALTCalliditas Therapeutics AB
15/05/202409:30PR Newswire (US)Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in StockholmNASDAQ:CALTCalliditas Therapeutics AB
15/05/202408:36PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)NASDAQ:CALTCalliditas Therapeutics AB
14/05/202408:52PR Newswire (US)Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in ChinaNASDAQ:CALTCalliditas Therapeutics AB
06/05/202403:16PR Newswire (US)Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibNASDAQ:CALTCalliditas Therapeutics AB
24/04/202414:35PR Newswire (US)Calliditas Therapeutics' 2023 Annual Report PublishedNASDAQ:CALTCalliditas Therapeutics AB
24/04/202404:30PR Newswire (US)Calliditas Announces Positive NefIgArd Open Label Extension ResultsNASDAQ:CALTCalliditas Therapeutics AB
18/04/202408:13PR Newswire (US)Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024NASDAQ:CALTCalliditas Therapeutics AB
09/04/202408:24PR Newswire (US)Calliditas Therapeutics to Attend Conferences in AprilNASDAQ:CALTCalliditas Therapeutics AB
08/04/202409:38PR Newswire (US)Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos AiresNASDAQ:CALTCalliditas Therapeutics AB
08/04/202404:24PR Newswire (US)Calliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatmentNASDAQ:CALTCalliditas Therapeutics AB
 Apresentando as notícias mais relevantes sobre:NASDAQ:CALT

Seu Histórico Recente

BOV
FICT3
Fictor Alimentos ON
BOV
IBOV
Índice Bovespa
BOV
ONCO3
Oncoclinicas Brasil Serv... ON
BOV
BOBR4
BOMBRIL PN
BOV
IRBR3
IRB BRASIL ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados